Prof. PeptideProf. Peptide

November 16, 2026

Health Canada Finds Bacteria in a Seized Injectable Peptide in Ottawa

On November 12, 2026, Health Canada warned that lab testing found bacteria in an injectable peptide product seized from Sage & Summit Wellness Co., a store in Ottawa, Ontario. The store had sold unauthorized peptides in-store and online, some in vials labelled “For Research Purposes Only,” and has agreed to stop. The advisory does not say which of the seized products contained the bacteria.

What Health Canada found

Health Canada’s advisory says “lab testing found bacteria (Sphingomonas aquatilis/melonis) in an injectable peptide product seized from Sage & Summit Wellness Co., in Ottawa, ON (451 Preston Street).” The seizure “followed a consumer complaint that the store had been selling unauthorized peptides in-store and on its website.” The store “agreed to stop selling unauthorized peptide products in-store and on its website as a result of Health Canada’s compliance and enforcement actions.”

Health Canada says it “will continue to seize unauthorized peptide products and disrupt distribution channels,” and will keep working with the Canada Border Services Agency “to stop unauthorized peptide shipments from entering the country.” In Canada, the advisory notes, “injectable peptides are generally regulated as prescription drugs,” and “selling unauthorized health products is illegal.”

What was seized

The advisory lists the unauthorized products by the names on their labels:

What the advisory does not say

The advisory names the bacteria and the store, but not the product: it refers only to “an injectable peptide product.” What the finding shows is about the supply channel, unauthorized vials sold over the counter and online, some labelled for research, rather than about any one of the compounds on the list.

The advisory also lists general risks of unauthorized peptides that apply across the category, not findings about these vials.

The “research use only” label

“Some of the seized vials were labelled as ‘For Research Purposes Only,’ which means the product was manufactured for lab use only, not for human use,” the advisory says, and “this type of labelling also does not make these products legal or exempt from regulatory requirements.” The same argument runs through Lilly’s lawsuits against US research-use sellers of retatrutide.

What Health Canada tells consumers

Health Canada’s own instructions in the advisory, quoted:

  • “Injecting contaminated products can cause serious infections, hospitalization, and in severe cases, life-threatening sepsis. The risk of infection is higher in people with a compromised immune system.”
  • “If you have injected it and you develop redness, swelling, pain at the injection site, fever, or chills, seek immediate medical attention.”
  • Authorized products carry “an eight-digit Drug Identification Number (DIN) or Natural Product Number (NPN)” on the label.

How it compares with the US position

Several of the seized compounds sit under a different rule in the United States. HHS’s draft Enforcement Discretion Policy of October 30, 2026 says HHS does not intend to act against 503A pharmacies compounding BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon on a prescription and under ten conditions, among them ingredients from FDA-registered manufacturers with lot-specific testing; it does nothing for research-use sellers. The conditions and the comments filed on it are in the report on the HHS policy, and the reported harms of unapproved retatrutide in the JAMA Network Open and BMJ case reports.

Sources

This article is for informational and educational purposes only and does not constitute medical advice. It reports a government advisory; it makes no safety, efficacy or quality claim about any product or vendor.

Checked and updated